ACHE and Alzheimer disease: As a reversible acetylcholinesterase (AChE) inhibitor and nicotinic acetylcholine receptor modulator, this compound has been approved by the U.S. Food and Drug Administration (FDA) for the clinical treatment of AD (Howes and Houghton, 2003).